NCT06099093View on ClinicalTrials.gov

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Carcinoma
Interventions
DRUG

18F-DCFPyl

Fluorine-labeled small molecule, via intravenous infusion per protocol.

Trial Locations (2)

02115

RECRUITING

Dana Farber Cancer Institute, Boston

02215

RECRUITING

Brigham and Womens Hospital, Boston

All Listed Sponsors
collaborator

Progenics Pharmaceuticals, Inc.

INDUSTRY

lead

Brigham and Women's Hospital

OTHER